Oncogenic metabolic reprogramming in breast cancer: focus on signaling pathways and mitochondrial genes

Med Oncol. 2023 May 11;40(6):174. doi: 10.1007/s12032-023-02037-2.

Abstract

Oncogenic metabolic reprogramming impacts the abundance of key metabolites that regulate signaling and epigenetics. Metabolic vulnerability in the cancer cell is evident from the Warburg effect. The research on metabolism in the progression and survival of breast cancer (BC) is under focus. Oncogenic signal activation and loss of tumor suppressor are important regulators of tumor cell metabolism. Several intrinsic and extrinsic factors contribute to metabolic reprogramming. The molecular mechanisms underpinning metabolic reprogramming in BC are extensive and only partially defined. Various signaling pathways involved in the metabolism play a significant role in the modulation of BC. Notably, PI3K/AKT/mTOR pathway, lactate-ERK/STAT3 signaling, loss of the tumor suppressor Ras, Myc, oxidative stress, activation of the cellular hypoxic response and acidosis contribute to different metabolic reprogramming phenotypes linked to enhanced glycolysis. The alterations in mitochondrial genes have also been elaborated upon along with their functional implications. The outcome of these active research areas might contribute to the development of novel therapeutic interventions and the remodeling of known drugs.

Keywords: BC; Metabolic reprogramming; Mitochondria; Signaling.

Publication types

  • Review

MeSH terms

  • Genes, Mitochondrial
  • Glycolysis / genetics
  • Humans
  • Neoplasms* / pathology
  • Phosphatidylinositol 3-Kinases* / metabolism
  • Signal Transduction / genetics

Substances

  • Phosphatidylinositol 3-Kinases